Histotripsy is a non-invasive treatment that uses focused sound waves to mechanically destroy tumor tissue from outside the body, without incisions, radiation, or heat. Cleared by the FDA in 2023 for liver tumors, it's one of the newest tools in the cancer treatment landscape, and it's generating attention for reasons that go beyond how it removes a tumor: emerging research suggests it may also help the immune system recognize and fight cancer elsewhere in the body. For patients and caregivers trying to understand where histotripsy fits alongside surgery, ablation, and radiation, here's what the science and the clinical data actually show.
What Is Histotripsy?
Histotripsy is a non-thermal, non-invasive therapy that uses focused ultrasound energy to create controlled acoustic cavitation, tiny, rapidly forming and collapsing bubbles that mechanically break apart and liquefy targeted tissue at the cellular level. Unlike radiofrequency ablation or microwave ablation, which destroy tissue by heating it, histotripsy relies entirely on mechanical force. No probes or needles are inserted into the body, and no radiation is delivered. It preserves healthy structures like blood vessels and bile ducts because they can flex under the acoustic pressure, while the more rigid tumor tissue is broken down into a liquid that the body naturally absorbs over time.
How the Histotripsy Procedure Works
During a histotripsy procedure, a physician uses real-time ultrasound or imaging guidance to focus sound wave pulses precisely onto the tumor. This real-time visualization is one of histotripsy's defining features: doctors can watch the tissue destruction happen live, adjusting the treatment as needed, a level of direct feedback that thermal ablation methods don't offer in the same way.
Because the procedure is performed through the skin with no incision required, patients typically experience less pain and a shorter recovery than they would with surgical tumor removal. Most histotripsy procedures for liver tumors are completed in a single outpatient or short-stay session, though the exact protocol depends on tumor size, location, and a patient's overall treatment plan.
Is Histotripsy FDA Approved?
Yes. On October 9, 2023, the FDA granted marketing authorization to the HistoSonics Edison System through its De Novo pathway, making it the first and only histotripsy platform cleared for use in the United States. The clearance covers the non-invasive destruction of liver tumor tissue, including cases considered unresectable, meaning tumors that couldn't safely be removed with traditional surgery.
That clearance was supported by the #HOPE4LIVER clinical trials, which enrolled 44 patients across 13 sites and treated a mix of hepatocellular carcinoma (18 cases) and metastatic liver tumors from other cancers (26 cases). The trials reported a 95.5% technical success rate in precisely targeting and destroying the intended tissue, with a low rate of serious complications (three Grade 3+ adverse events across all 44 patients).
Actively in the FDA pipeline: Kidney tumors. HistoSonics submitted the Edison System for FDA approval of a kidney tumor indication in 2026, so that could become the second officially cleared use relatively soon.
Under active research, not yet cleared: Pancreatic, breast, bone, and brain tumors are all being studied for histotripsy treatment, along with the intriguing immune response. Early research suggests treating a tumor with histotripsy might help the immune system recognize and attack cancer elsewhere in the body, which researchers are exploring as a way to boost immunotherapy's effectiveness across cancer types.
Histotripsy vs. Other Tumor Treatments
For patients weighing options, it helps to understand where histotripsy differs from more established therapies:
Surgical resection physically removes the tumor and surrounding tissue but requires an incision, anesthesia, and a longer recovery, and isn't always an option for tumors near major blood vessels or for patients who aren't strong enough for surgery. Radiofrequency and microwave ablation use heat delivered through a needle to destroy tissue, but heat-based methods can struggle near blood vessels, which act as a heat sink and can protect nearby cancer cells from full destruction. Radiation therapy delivers ionizing radiation over multiple sessions and carries its own set of side effects tied to radiation exposure.
Histotripsy is non-thermal and non-ionizing, requires no needle or incision, and its mechanical action isn't blocked by nearby blood flow the way heat-based ablation can be. That doesn't make it a universal replacement for these treatments; candidacy still depends on tumor size, location, liver function, and overall health, but it does give physicians another option, particularly for patients whose tumors haven't responded well to, or aren't good candidates for, existing approaches.
Histotripsy Side Effects
As with any tumor treatment, histotripsy carries some risk, though early clinical data suggests a relatively favorable safety profile compared to invasive alternatives. Reported side effects in clinical trials have generally been mild to moderate and can include pain or soreness at the treatment site, temporary changes in liver enzyme levels, fatigue, and in a smaller number of cases, more serious complications requiring additional care. Because histotripsy destroys tissue mechanically rather than surgically removing it, the liquefied tissue is absorbed by the body over the following weeks, which patients should discuss with their care team so they know what post-procedure recovery and follow-up imaging to expect.
Could Histotripsy Help the Immune System Fight Cancer?
One of the more striking areas of ongoing research is histotripsy's potential effect on the immune system. Because the treatment mechanically ruptures tumor cells rather than cooking or cutting them out, it releases tumor-associated antigens and cellular debris into the body in a way that appears to alert the immune system to the cancer's presence. Early studies, including work published in peer-reviewed journals and presented at cancer research conferences, have observed what's sometimes called an "abscopal effect", a response where treating one tumor site appears to trigger immune activity against untreated tumors elsewhere in the body.
Researchers are also exploring whether combining histotripsy with immunotherapy could make cancers that are typically resistant to immune-based treatment more responsive. This research is still early, largely in animal models and small clinical observations, but it represents one of the more promising directions for how mechanical tumor destruction might work alongside, rather than instead of, systemic cancer therapies. Patients interested in this angle should ask their care team whether any histotripsy-immunotherapy combination trials are currently enrolling.
Who Might Be a Candidate for Histotripsy?
Right now, histotripsy's FDA-cleared use is limited to liver tumors, both primary liver cancer (hepatocellular carcinoma) and tumors that have spread to the liver from other cancers. Whether it's the right choice depends on factors like tumor size and number, location relative to major blood vessels and bile ducts, remaining healthy liver function, and how a patient has responded to prior treatments. It is generally considered for patients who aren't candidates for surgical resection, or as an additional tool alongside other therapies.
Because access to Edison Systems is still limited to specific hospitals and cancer centers that have adopted the technology, patients interested in histotripsy should ask their oncology team whether a nearby facility offers it, or whether a clinical trial testing histotripsy for their specific cancer type is currently open.
The Bottom Line
Histotripsy represents a genuinely new category of cancer treatment: one that destroys tumors mechanically, without heat, radiation, or incisions, while showing early signs of activating the body's own immune response against cancer. It's currently FDA-cleared only for liver tumors, with research into other cancer types actively underway. As with any treatment decision, patients and caregivers should talk with their full care team about whether histotripsy fits their specific diagnosis, treatment history, and goals of care.
